Close Menu

chlamydia

The funding will go toward expanding the firm's product line and increasing access to its testing services. MyLab Box has raised $2.1 million in total.

The Ann Arbor, Michigan-based firm will compete with a few well-established players offering systems that can run in vitro diagnostic tests as well as lab-developed tests. 

The award will go toward development of Talis Bio's SlipChip POC technology for pathogen identification and antibiotic-susceptibility testing.

The firm expects to build out a menu for the reader, which will automate results reporting for colorimetric- and fluorescence-based tests.

The company unveiled forthcoming products for high-throughput molecular testing, diagnostic lab informatics, and microbiology automation.

The test has been validated for use with the same full set of female urogenital specimens that are used with Cobas NT/NG testing, as well as for use with male urine. 

The clinic, a partnership of the Florida Department of Health in Broward County and the AIDS Healthcare Foundation hopes to improve STD treatment and control.

While molecular testing is now routine in cancer and women's health, for other disease areas, the technology may be overkill, Sundin said. 

The firm launched the service in part because it recognized that consumers increasingly prefer to pay for their healthcare services out of pocket and without having to get physician referrals. 

The test runs on the firm's high throughput platforms and has claims for extragenital samples in addition to traditional samples.

Pages